Current antithrombotic drugs, including widely used antiplatelet agents and anticoagulants, are associated with significant bleeding risk. Emerging experimental evidence suggests that the molecular and cellular mechanisms of hemostasis and thrombosis can be separated, thereby increasing the possibility of new antithrombotic therapeutic targets with reduced bleeding risk. We review new coagulation and platelet targets and highlight the interaction between integrin αMβ2 (Mac-1, CD11b/CD18) on leukocytes and GPIbα on platelets that seems to distinguish thrombosis from hemostasis.

Thrombotic cardiovascular diseases, including myocardial infarction and stroke, are the leading cause of death in developed countries.1  Currently used antithrombotic drugs, including antiplatelet agents and anticoagulants, are associated with significant bleeding risk, which increases morbidity and mortality.2-4  Must we accept that the inhibition of thrombosis is inextricably linked to compromised hemostasis? In fact, there is growing evidence that the molecular and cellular mechanisms governing hemostasis and thrombosis5  can be distinguished or at least separated sufficiently to allow for selective therapeutic interventions. If the pathologic event, thrombosis, can be suppressed with limited perturbation of hemostasis, an antithrombotic strategy with reduced bleeding might be realized. In this article, we summarize recent findings that specific molecular events can suppress thrombosis while sparing hemostasis. Some candidate targets with such discriminatory activities remain platelet-associated or coagulation system targets, but they might still necessitate delicately balancing their antithrombotic and antihemostatic activities. Large-scale trials in different clinical settings will be required to determine whether such agents offer therapeutic advantages over current antithrombotic agents. Nevertheless, the discriminating activity of such agents supports the possibility that thrombosis and hemostasis can be distinguishable events. We focused our attention on the unexpected role of a particular membrane protein on leukocytes that can be targeted to selectively suppress thrombosis without apparent compromise of hemostasis. Blockade of the interaction of integrin Mac-1 on leukocytes with 1 of its cognate ligands, GPIbα, on platelets might afford a sufficiently wide therapeutic window between thrombosis and hemostasis to serve as a safer therapeutic target.

Recent studies have suggested that specific components of the blood coagulation system may be targeted to limit thrombosis without severely comprising hemostasis (Table 1). Falling into this category are factor XI (FXI) and factor XII (FXII) as targets and their inhibitors as therapeutic agents. As reviewed by Weitz and colleagues,6,7  FXI and FXII have emerged as targets to prevent thrombosis without severe perturbation of hemostasis. Humans with FXI deficiency rarely bleed spontaneously, and individuals with FXII deficiency do not bleed. In fact, the first patient reported with deficiency of FXII died of pulmonary thromboembolic disease.8  Nevertheless, mice deficient in FXI or FXII have reduced thrombosis.9,10  Targeting the activities of these factors with antibodies, antisense oligomers, or aptamers has been reported to inhibit thrombosis in mouse models without or with only modestly increased bleeding times.6  Importantly, an antisense oligonucleotide that specifically reduces FXI levels was effective at preventing postoperative venous thromboembolism in patients undergoing elective primary unilateral total knee arthroplasty; however, bleeding was increased with antisense FXI compared with enoxaparin (8% vs 3%).11  Despite the encouraging preclinical and phase 2 clinical data, because FXI deficiency can be associated with bleeding and because FXII deficiency can be associated with thrombosis, it seems likely that careful dosing, monitoring, and/or development of effective antidotes will be needed for these targets to progress toward acceptance.

Another key area of research that supports the feasibility of targeting thrombosis that does not compromise hemostasis is the platelet in general and its ligand-receptor interactions in particular (Table 1). Included in this category is CD40 ligand (CD40L). CD40L is released from platelets during thrombus formation, is a ligand for GIIb-IIIa,12  and stimulates outside-in signaling.13  Gas6 and its tyrosine kinase receptors (mer, tyro3, and axl)14,15  are involved in thrombus formation and stabilization in both murine and human platelets. Ephrins and their eph kinase receptors,16  ATP-gated P2X1 cation channel,17  and myeloid-related protein-8/14 (MRP-8/14 or S100A8/A9) and its platelet CD36 receptor18  are ligand-receptor pairings that act within the platelet-platelet contact zone or synapse after the initial aggregation event and ultimately promote thrombus growth and stability.19  Importantly, mice with genetic defects in each of these ligand-receptor interactions have impaired thrombus formation with apparently intact hemostasis as determined by bleeding time assays. In addition, certain intracellular ligands, which bind to or alter critical interfaces and interactions of receptors such as Gα1320,21  or integrin peptides22,23  can interfere with thrombosis without perturbing hemostasis. These studies support the premise that thrombosis and hemostasis are distinguishable events. However, the complex organization of the thrombus and the heterogeneity of platelets within the thrombus24  make it uncertain whether the limitations of current antiplatelet drugs can be significantly reduced. Of concern, for example, is the observation that monoclonal antibody against CD40L was associated with unexpected thrombotic complications.25 

Interactions of GPIbα with its binding partners have also been considered as antithrombotic targets. ARC1779, an aptamer that blocks binding of the A1 domain of von Willibrand factor (vWF) to GPIbα, has been tested in humans as a potential treatment for patients with refractory thrombocytopenic purpura and type 2b von Willebrand disease26,27  as well as for patients undergoing carotid endarterectomy.28  However, targeting GPIb carries the stigma of hemostatic perturbations associated with Bernard-Soulier syndrome. Indeed, ARC1779 was effective in reducing thromboembolic signals detected by transcranial Doppler ultrasonography in patient undergoing carotid endarterectomy but was associated with increased perioperative bleeding and anemia.28 

Inflammation has been linked to all stages of the development of vulnerable atherosclerotic plaque and its thrombotic complications. Leukocyte count29  and leukocyte activation (as determined by plasma levels of the secreted leukocyte enzyme myeloperoxidase)30  are predictive of future myocardial infarction. Circulating leukocyte-platelet conjugates are also predictive of myocardial infarction31  and are a more sensitive marker of in vivo platelet activation than platelet surface P-selectin.32  A recent study from our group33  provides an independent line of evidence that physiologic hemostasis and pathologic thrombosis are mechanistically different processes. This study implicates the heterotypic cell-cell interactions between leukocytes and platelets in thrombus formation and suggests that the leukocyte could be an antithrombotic target.

In a series of articles written since 2000, our laboratories have identified the essential importance of leukocyte β2-integrin Mac-1 (also known as αMβ2, CD11b/CD18) and its counter-receptor, platelet GPIbα, in mediating leukocyte-platelet interactions in vitro and in vivo.34-36  The αMI domain of Mac-1 contributes broadly to the recognition of many of its ligands37  and specifically to the binding of GPIbα.34  GPIbα is the largest (135 kDa) subunit of the GPIbα/β/GPIX/GPV complex with ∼25 000 copies found on the surface of platelets.38  The primary (broadly accepted) role of GPIbα in hemostasis is its ability to serve as a receptor for vWF and thrombin.38  Indeed, GPIb has been investigated as an antithrombotic target, but the severity of bleeding in patients with GPIb deficiency (ie, Bernard-Soulier syndrome) has dampened enthusiasm for its therapeutic targeting. Working from the Mac-1 side, we localized a binding site for GPIbα within the αMI domain segment αM(P201-K217) by using a homologous scanning mutagenesis strategy35  that was based on the differential binding of GPIbα to the αMI and αLI domains. This strategy was complemented by several independent approaches, including synthetic peptides, site-directed mutagenesis, and gain-in-function analyses. Ultimately, 2 amino acids critical for this interaction (human T213 and R216) were identified.35  Antibody targeting of αM(P201-K217) blocked αMβ2-dependent adhesion to GPIbα, but not to several other Mac-1 ligands. It also inhibited leukocyte accumulation, cellular proliferation, and neointimal thickening after arterial injury,36  and it broadly regulated the biological response to tissue injury in models of glomerulonephritis39  and experimental autoimmune encephalomyelitis.40 

Because leukocyte-platelet interactions bidirectionally induce signals that amplify proinflammatory and prothrombotic cellular responses,41  we hypothesized that leukocyte Mac-1 engagement of platelet GPIbα is critical for thrombus formation. We reported recently33  that mice with Mac-1 deficiency (Mac-1−/−) or mutation of the Mac-1 binding site (mouse S213A/R216A) for GPIbα have delayed thrombosis after carotid artery and cremaster microvascular injury without affecting multiple parameters of hemostasis. Antibody and small molecule interference with the Mac-1:GPIbα interaction inhibited thrombosis.

It has been proposed that after initial aggregation, platelets form a synapse that facilitates signaling by membrane-tethered receptor-ligand pairs and localizing secreted and shed ligands that ultimately promote thrombus growth and stability.19  Our findings suggest that leukocyte-platelet interactions mediated by Mac-1:GPIbα also seem to function in this synapse. Prior work from our laboratories demonstrated that leukocyte engagement of platelet GPIbα via Mac-1 induces platelet outside-in signaling and platelet activation dependent upon Akt phosphorylation.42  Engagement of platelet GPIbα via Mac-1 induces outside-in Mac-1 signaling that leads to phosphorylation of PKC δ and downregulation of Foxp1 in monocytic cells.33  Thus, blockade of the initial cell-cell conjugation mediated by Mac-1:GPIbα may prevent bidirectional signaling that amplifies thrombus formation and accounts for the effectiveness of Mac-1:GPIbα inhibition in reducing occlusive thrombus formation in vivo.

Our observations suggest a possible target for therapeutic intervention in cardiovascular and thrombotic diseases. In particular, the specificity of antibodies or small molecules with inhibitory action toward Mac-1:GPIbα suggests that it might be possible to inhibit prothrombotic leukocyte-platelet interactions without affecting other Mac-1 functions or perturbing hemostasis. Bleeding times were not prolonged in mice that were deficient in Mac-1 or that had a mutated GPIbα binding site.33  Our study identified glucosamine as a prototype of 1 small molecule antagonist of the Mac-1:GPIbα interaction. The failure of other molecules with size and composition similar to that of glucosamine to block αMI domain:GPIbα interaction augers well for the possibility of detailed structure-activity analyses that could identify more potent small molecule antagonists. Our structural modeling study suggested that several closely related binding modes would allow glucosamine to bind in close to T213/R216 and interfere with GPIbα binding. Neither glucosamine nor our antipeptide block αMI P201-K217 antibody prolonged tail bleeding times in mice.33  Other small molecules unrelated to glucosamine were also identified as Mac-1:GPIbα inhibitors. Ultimately, solving the crystal structure of glucosamine or other small molecules identified in our screen or of an anti-M2 bound to the αMI domain may lead to a new class of antithrombotic therapy.

At a more fundamental level, the results of this study suggest that thrombosis and hemorrhage may be uncoupled at the level of the Mac-1:GPIbα interaction. In particular, the specificity of an antibody or small molecule with an inhibitory action selective for Mac-1:GPIbα might inhibit prothrombotic effects of leukocyte-platelet interactions without affecting other Mac-1 functions. In mice, deficiency of Mac-1 did not interfere with multiple parameters of hemostasis including tail bleeding time, platelet activation and spreading, and plasma coagulation activity (ie, activated partial thromboplastin time and thrombin generation). The identification of a new leukocyte-platelet–dependent pathway of thrombosis that is not required for the arrest of bleeding has significant clinical implications and several limitations. First, the bleeding times in mice are only a crude measure of hemostasis, and it is uncertain whether murine models of thrombosis and hemostasis are predictive of human responses. The proposition that antithrombotic function of inhibitors of the Mac-1:GPIbα interaction may translate to human biology is supported by the recent results of the CANTOS (Canakinumab Anti-inflammatory Thrombosis Outcome Study) trial involving more than 10 000 patients in whom an anti-inflammatory drug (a humanized anti-interleukin-1β [IL-1β] antibody that had no lipid-lowering effects) reduced primary and secondary thrombotic cardiovascular end points, which provides direct evidence for the inflammatory hypothesis of atherothrombotic disease.43  Although the antithrombotic effects of the IL-1β antibody were modest but significant, they support the premise that interference with an inflammatory reaction, leukocyte-platelet conjugation mediated by Mac-1:GPIbα interaction, may be antithrombotic in humans.

However, even if a Mac-1:GPIbα inhibitor of appropriate specificity and potency is identified, the route and timing of administration relative to the thrombotic event and adverse effects associated with the dissipation or discontinuation of the antagonist are challenging issues. Extensive preclinical and clinical testing will be required to determine whether the interaction between leukocyte Mac-1 and platelet GPIbα represents an effective and safe target. In our published articles,33,35  we describe extensive binding studies that used wild-type and mutant αMI domains to identify the binding site within Mac-1 for GPIbα. The region within Mac-1 (αM P201-K217) responsible for binding to GPIbα is distinct from other Mac-1 ligands. Importantly, the binding of multiple other Mac-1 ligands essential for innate immunity, including ICAM-1, iC3b, CD40L, and fibrinogen, was unaffected by mutation of the 2 amino acids required for GPIbα binding. Nonetheless, because patients with deficiency of β2-integrins, including LFA-1, Mac-1, and p150,95, suffer from recurrent infections44  and because Mac-1–deficient mice have leukocytosis and impaired innate immunity and wound healing,45  development of specific inhibitors of Mac-1:GPIbα will require careful surveillance for infectious complications. Finally, we have elected to pursue inhibitors that bind Mac-1 rather than GPIbα to avoid thrombocytopenia that may accompany the binding of platelet receptors, albeit rarely. Nevertheless, the preliminary data do position the Mac-1:GPIbα interaction to be considered a novel and targetable mediator of thrombosis with potentially reduced bleeding risk.

The authors thank Kamila Bledzka for her assistance with the manuscript.

This work was supported by National Institutes of Health, National Heart, Lung, and Blood Institute grants P01HL073311 and R01 HL096062 (E.F.P.) and R37 HL57506 and R01 HL126645 (D.I.S.).

Contribution: E.F.P. and D.I.S. wrote the paper; and Y.W. critically reviewed the paper.

Conflict-of-interest disclosure: E.F.P., Y.W., and D.I.S. are coinventers of technology related to Mac-1:GPIbα assigned to Case Western Reserve University and licensed to Sujana Biotech.

Correspondence: Daniel I. Simon, University Hospitals Cleveland Medical Center, 11100 Euclid Ave, Cleveland, OH 44106; e-mail: daniel.simon@uhhospitals.org.

1.
Lloyd-Jones
D
,
Adams
R
,
Carnethon
M
, et al
;
American Heart Association Statistics Committee and Stroke Statistics Subcommittee
.
Heart disease and stroke statistics--2009 update: a report from the American Heart Association Statistics Committee and Stroke Statistics Subcommittee
.
Circulation
.
2009
;
119
(
3
):
e21
-
e181
.
2.
Eikelboom
JW
,
Mehta
SR
,
Anand
SS
,
Xie
C
,
Fox
KA
,
Yusuf
S
.
Adverse impact of bleeding on prognosis in patients with acute coronary syndromes
.
Circulation
.
2006
;
114
(
8
):
774
-
782
.
3.
Stone
GW
,
Witzenbichler
B
,
Guagliumi
G
, et al
;
HORIZONS-AMI Trial Investigators
.
Bivalirudin during primary PCI in acute myocardial infarction
.
N Engl J Med
.
2008
;
358
(
21
):
2218
-
2230
.
4.
Mehran
R
,
Lansky
AJ
,
Witzenbichler
B
, et al
;
HORIZONS-AMI Trial Investigators
.
Bivalirudin in patients undergoing primary angioplasty for acute myocardial infarction (HORIZONS-AMI): 1-year results of a randomised controlled trial
.
Lancet
.
2009
;
374
(
9696
):
1149
-
1159
.
5.
Sachs
UJ
,
Nieswandt
B
.
In vivo thrombus formation in murine models
.
Circ Res
.
2007
;
100
(
7
):
979
-
991
.
6.
Weitz
JI
.
Factor XI and factor XII as targets for new anticoagulants
.
Thromb Res
.
2016
;
141
(
Suppl 2
):
S40
-
S45
.
7.
Weitz
JI
,
Fredenburgh
JC
.
Factors XI and XII as targets for new anticoagulants
.
Front Med (Lausanne)
.
2017
;
4
:
19
.
8.
Caen
J
,
Wu
Q
.
Hageman factor, platelets and polyphosphates: early history and recent connection
.
J Thromb Haemost
.
2010
;
8
(
8
):
1670
-
1674
.
9.
Renné
T
,
Oschatz
C
,
Seifert
S
, et al
.
Factor XI deficiency in animal models
.
J Thromb Haemost
.
2009
;
7
(
Suppl 1
):
79
-
83
.
10.
Kleinschnitz
C
,
Stoll
G
,
Bendszus
M
, et al
.
Targeting coagulation factor XII provides protection from pathological thrombosis in cerebral ischemia without interfering with hemostasis
.
J Exp Med
.
2006
;
203
(
3
):
513
-
518
.
11.
Büller
HR
,
Bethune
C
,
Bhanot
S
, et al
;
FXI-ASO TKA Investigators
.
Factor XI antisense oligonucleotide for prevention of venous thrombosis
.
N Engl J Med
.
2015
;
372
(
3
):
232
-
240
.
12.
André
P
,
Prasad
KS
,
Denis
CV
, et al
.
CD40L stabilizes arterial thrombi by a beta3 integrin--dependent mechanism
.
Nat Med
.
2002
;
8
(
3
):
247
-
252
.
13.
Prasad
KS
,
Andre
P
,
He
M
,
Bao
M
,
Manganello
J
,
Phillips
DR
.
Soluble CD40 ligand induces beta3 integrin tyrosine phosphorylation and triggers platelet activation by outside-in signaling
.
Proc Natl Acad Sci USA
.
2003
;
100
(
21
):
12367
-
12371
.
14.
Angelillo-Scherrer
A
,
Burnier
L
,
Flores
N
, et al
.
Role of Gas6 receptors in platelet signaling during thrombus stabilization and implications for antithrombotic therapy
.
J Clin Invest
.
2005
;
115
(
2
):
237
-
246
.
15.
Cosemans
JM
,
Van Kruchten
R
,
Olieslagers
S
, et al
.
Potentiating role of Gas6 and Tyro3, Axl and Mer (TAM) receptors in human and murine platelet activation and thrombus stabilization
.
J Thromb Haemost
.
2010
;
8
(
8
):
1797
-
1808
.
16.
Prévost
N
,
Woulfe
DS
,
Tognolini
M
, et al
.
Signaling by ephrinB1 and Eph kinases in platelets promotes Rap1 activation, platelet adhesion, and aggregation via effector pathways that do not require phosphorylation of ephrinB1
.
Blood
.
2004
;
103
(
4
):
1348
-
1355
.
17.
Hechler
B
,
Lenain
N
,
Marchese
P
, et al
.
A role of the fast ATP-gated P2X1 cation channel in thrombosis of small arteries in vivo
.
J Exp Med
.
2003
;
198
(
4
):
661
-
667
.
18.
Wang
Y
,
Fang
C
,
Gao
H
, et al
.
Platelet-derived S100 family member myeloid-related protein-14 regulates thrombosis
.
J Clin Invest
.
2014
;
124
(
5
):
2160
-
2171
.
19.
Brass
LF
,
Zhu
L
,
Stalker
TJ
.
Minding the gaps to promote thrombus growth and stability
.
J Clin Invest
.
2005
;
115
(
12
):
3385
-
3392
.
20.
Shen
B
,
Zhao
X
,
O’Brien
KA
, et al
.
A directional switch of integrin signalling and a new anti-thrombotic strategy
.
Nature
.
2013
;
503
(
7474
):
131
-
135
.
21.
Schiemer
J
,
Bohm
A
,
Lin
L
, et al
.
Gα13 switch region 2 relieves talin autoinhibition to activate αIIbβ3 integrin
.
J Biol Chem
.
2016
;
291
(
52
):
26598
-
26612
.
22.
Stefanini
L
,
Ye
F
,
Snider
AK
, et al
.
A talin mutant that impairs talin-integrin binding in platelets decelerates αIIbβ3 activation without pathological bleeding
.
Blood
.
2014
;
123
(
17
):
2722
-
2731
.
23.
Estevez
B
,
Shen
B
,
Du
X
.
Targeting integrin and integrin signaling in treating thrombosis
.
Arterioscler Thromb Vasc Biol
.
2015
;
35
(
1
):
24
-
29
.
24.
Stalker
TJ
,
Welsh
JD
,
Brass
LF
.
Shaping the platelet response to vascular injury
.
Curr Opin Hematol
.
2014
;
21
(
5
):
410
-
417
.
25.
Kawai
T
,
Andrews
D
,
Colvin
RB
,
Sachs
DH
,
Cosimi
AB
.
Thromboembolic complications after treatment with monoclonal antibody against CD40 ligand
.
Nat Med
.
2000
;
6
(
2
):
114
.
26.
Gilbert
JC
,
DeFeo-Fraulini
T
,
Hutabarat
RM
, et al
.
First-in-human evaluation of anti von Willebrand factor therapeutic aptamer ARC1779 in healthy volunteers
.
Circulation
.
2007
;
116
(
23
):
2678
-
2686
.
27.
Jilma-Stohlawetz
P
,
Gorczyca
ME
,
Jilma
B
,
Siller-Matula
J
,
Gilbert
JC
,
Knöbl
P
.
Inhibition of von Willebrand factor by ARC1779 in patients with acute thrombotic thrombocytopenic purpura
.
Thromb Haemost
.
2011
;
105
(
3
):
545
-
552
.
28.
Markus
HS
,
McCollum
C
,
Imray
C
,
Goulder
MA
,
Gilbert
J
,
King
A
.
The von Willebrand inhibitor ARC1779 reduces cerebral embolization after carotid endarterectomy: a randomized trial
.
Stroke
.
2011
;
42
(
8
):
2149
-
2153
.
29.
Shah
AD
,
Denaxas
S
,
Nicholas
O
,
Hingorani
AD
,
Hemingway
H
.
Neutrophil Counts and Initial Presentation of 12 Cardiovascular Diseases: A CALIBER Cohort Study
.
J Am Coll Cardiol
.
2017
;
69
(
9
):
1160
-
1169
.
30.
Brennan
ML
,
Penn
MS
,
Van Lente
F
, et al
.
Prognostic value of myeloperoxidase in patients with chest pain
.
N Engl J Med
.
2003
;
349
(
17
):
1595
-
1604
.
31.
Furman
MI
,
Barnard
MR
,
Krueger
LA
, et al
.
Circulating monocyte-platelet aggregates are an early marker of acute myocardial infarction
.
J Am Coll Cardiol
.
2001
;
38
(
4
):
1002
-
1006
.
32.
Michelson
AD
,
Barnard
MR
,
Krueger
LA
,
Valeri
CR
,
Furman
MI
.
Circulating monocyte-platelet aggregates are a more sensitive marker of in vivo platelet activation than platelet surface P-selectin: studies in baboons, human coronary intervention, and human acute myocardial infarction
.
Circulation
.
2001
;
104
(
13
):
1533
-
1537
.
33.
Wang
Y
,
Gao
H
,
Shi
C
, et al
.
Corrigendum: Leukocyte integrin Mac-1 regulates thrombosis via interaction with platelet GPIbα
.
Nat Commun
.
2017
;
8
:
16124
.
34.
Simon
DI
,
Chen
Z
,
Xu
H
, et al
.
Platelet glycoprotein Ibalpha is a counterreceptor for the leukocyte integrin Mac-1 (CD11b/CD18)
.
J Exp Med
.
2000
;
192
(
2
):
193
-
204
.
35.
Ehlers
R
,
Ustinov
V
,
Chen
Z
, et al
.
Targeting platelet-leukocyte interactions: identification of the integrin Mac-1 binding site for the platelet counter receptor glycoprotein Ibalpha
.
J Exp Med
.
2003
;
198
(
7
):
1077
-
1088
.
36.
Wang
Y
,
Sakuma
M
,
Chen
Z
, et al
.
Leukocyte engagement of platelet glycoprotein Ibalpha via the integrin Mac-1 is critical for the biological response to vascular injury
.
Circulation
.
2005
;
112
(
19
):
2993
-
3000
.
37.
Diamond
MS
,
Garcia-Aguilar
J
,
Bickford
JK
,
Corbi
AL
,
Springer
TA
.
The I domain is a major recognition site on the leukocyte integrin Mac-1 (CD11b/CD18) for four distinct adhesion ligands
.
J Cell Biol
.
1993
;
120
(
4
):
1031
-
1043
.
38.
López
JA
,
Dong
JF
.
Structure and function of the glycoprotein Ib-IX-V complex
.
Curr Opin Hematol
.
1997
;
4
(
5
):
323
-
329
.
39.
Hirahashi
J
,
Hishikawa
K
,
Kaname
S
, et al
.
Mac-1 (CD11b/CD18) links inflammation and thrombosis after glomerular injury
.
Circulation
.
2009
;
120
(
13
):
1255
-
1265
.
40.
Langer
HF
,
Choi
EY
,
Zhou
H
, et al
.
Platelets contribute to the pathogenesis of experimental autoimmune encephalomyelitis
.
Circ Res
.
2012
;
110
(
9
):
1202
-
1210
.
41.
Libby
P
,
Simon
DI
.
Inflammation and thrombosis: the clot thickens
.
Circulation
.
2001
;
103
(
13
):
1718
-
1720
.
42.
Pluskota
E
,
Woody
NM
,
Szpak
D
, et al
.
Expression, activation, and function of integrin alphaMbeta2 (Mac-1) on neutrophil-derived microparticles
.
Blood
.
2008
;
112
(
6
):
2327
-
2335
.
43.
Ridker
PM
,
Everett
BM
,
Thuren
T
, et al
;
CANTOS Trial Group
.
Antiinflammatory therapy with canakinumab for atherosclerotic disease
.
N Engl J Med
.
2017
;
377
(
12
):
1119
-
1131
.
44.
Springer
TA
,
Thompson
WS
,
Miller
LJ
,
Schmalstieg
FC
,
Anderson
DC
.
Inherited deficiency of the Mac-1, LFA-1, p150,95 glycoprotein family and its molecular basis
.
J Exp Med
.
1984
;
160
(
6
):
1901
-
1918
.
45.
Rosenkranz
AR
,
Coxon
A
,
Maurer
M
, et al
.
Impaired mast cell development and innate immunity in Mac-1 (CD11b/CD18, CR3)-deficient mice
.
J Immunol
.
1998
;
161
(
12
):
6463
-
6467
.
46.
Wolf
D
,
Hohmann
JD
,
Wiedemann
A
, et al
.
Binding of CD40L to Mac-1's I-domain involves the EQLKKSKTL motif and mediates leukocyte recruitment and atherosclerosis--but does not affect immunity and thrombosis in mice
.
Circ Res
.
2011
;
109
(
11
):
1269
-
1279
.
Sign in via your Institution